Extension Study Evaluating Treatment With Pf-05280586 Versus Rituximab In Subjects With Active Rheumatoid Arthritis Who Have Participated In Other Pf-05280586 Clinical Trials
Phase of Trial: Phase I/II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 11 Apr 2016 Planned number of patients changed from 157 to 184.
- 11 Apr 2016 Status changed from active, no longer recruiting to completed.